American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction

Gynecol Oncol. 2009 Oct;115(1):132-134. doi: 10.1016/j.ygyno.2009.06.006.
No abstract available

Publication types

  • Practice Guideline

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Aromatase Inhibitors / adverse effects
  • Aromatase Inhibitors / therapeutic use*
  • Breast Neoplasms / prevention & control*
  • Female
  • Fenretinide / adverse effects
  • Fenretinide / therapeutic use
  • Humans
  • Raloxifene Hydrochloride / adverse effects
  • Raloxifene Hydrochloride / therapeutic use*
  • Tamoxifen / adverse effects
  • Tamoxifen / therapeutic use*

Substances

  • Aromatase Inhibitors
  • Tamoxifen
  • Fenretinide
  • Raloxifene Hydrochloride